Live feed07:30:00·108dPRReleasevia QuantisnowAnavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's DiseaseByQuantisnow·Wall Street's wire, on your screen.AVXL· Anavex Life Sciences Corp.Health Care
